Trials / Recruiting
RecruitingNCT07006792
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lebrikizumab | Administered SC |
Timeline
- Start date
- 2025-06-16
- Primary completion
- 2026-04-01
- Completion
- 2026-09-01
- First posted
- 2025-06-05
- Last updated
- 2026-04-17
Locations
66 sites across 5 countries: United States, Argentina, Brazil, Canada, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07006792. Inclusion in this directory is not an endorsement.